Magnetic nanocomposite’s mechanism of action during the hyperthermia treatment of the breast cancer

2021 ◽  
Author(s):  
Mohammadhossein Shahsavari Alavijeh ◽  
Iman Rad ◽  
Shadie Hatamie
Keyword(s):  
Breast Cancer ◽  
Mechanism Of Action ◽  
Hyperthermia Treatment

Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti-Breast Cancer (MDA-MB-231, MCF-7) Agents.

2020 ◽  
Vol 20 ◽  
Author(s):  
Stefan Dimov ◽  
Anelia Ts. Mavrova ◽  
Denitsa Yancheva ◽  
Biliana Nikolova ◽  
Iana Tsoneva
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Mechanism Of Action ◽  
Biologically Active ◽  
Breast Cancer Cell Lines ◽  
3T3 Cells ◽  
Fluorescence Study ◽  
Compound 21 ◽  
Mutational Activation ◽  
Mcf 7

Aims: The purpose was the synthesis of some new thienopyrimidines derivative of 1,3-disubstituted benzimidazoles and the evaluation of their cytotoxicity towards MDA-MB-231 and MCF-7 cell lines as well 3T3 cells. Background: An overexpression or mutational activation of TK receptors EGFR and HER2/neu are characteristic for tumors. It has been found that some thieno[2,3-d]pyrimidines exhibit better inhibitory activity against epidermal growth factor receptor (EGFR/ErbB-2) tyrosine kinase in comparison to aminoquinazolines. Breast cancer activity towards MDAMB-231 and MCF-7 cell lines by inhibiting EGFR was revealed by a novel 2-arylbenzimidazole. This motivated the synthesis of new thienopyrimidines possessing benzimidazole fragment in order to evaluate their cytotoxicity to the above mentioned cell lines. Objective: The objectives were the design and synthesis of a novel series thieno[2,3-d]pyrimidines bearing biologically active moieties as 1,3-disubstituted-benzimidazole heterocycle structurally similar to diaryl ureas in order to evaluate their cytotoxicity against MDA-MB-231, MCF-7 breast cancer cell lines. Methods: N,N-disubstituted benzimidazole-2-one carbonitriles were synthesized by Aza-Michael addition and used as precursors to generate some of the new thieno[2,3-d]pyrimidines in acidic medium. The interaction of chloroethyl-2- thienopyrimidines and 2-amino-benzimidazole resp. benzimidazol-2-one nitriles under solid-liquid transfer catalysis conditions lead to obtaining of new thienopyrimidines. MTT assay for cells survival was performed in order to establish the cytotoxicity of the tested compounds. Fluorescence study was used to elucidate some aspect of mechanism. Results: The effect of nine of the synthesized compounds was investigated towards MDA-MB-231 and MCF-7 cells as well as to 3T3 cells. Thieno[2,3-d]pyirimidine-4-one 16 (IC50 – 0.058 μM) and 21 (IC50 – 0.029 μM) possess high cytotoxicity against MDA-MB-231 cells after 24h. The most toxic against breast cancer MCF-7 cells was compounds 21 (IC50 – 0.074 μM), revealing lower cytotoxicity towards mouse fibroblast 3T3 cells with IC50 – 0.20 μM. SAR analisys was performed. Fluorescence study of the treatment of MDA-MB cells with compound 21 was carried out in order to clarify some aspects of mechanism of action. Conclusion: The relationship between cytotoxicity of compounds 14 and 20 against MCF-7 and 3T3 cells can suggest a similar mechanism of action. The antitumor potential of the tested compounds proves the necessity for further investigation to estimate the exact inhibition pathway in the cellular processes. The fluorescence study of the treatment of MDA-MB cells with compound 21 showed a rapid process of apoptosis.

Portulaca oleracea L. polysaccharides enhance the immune efficacy of dendritic cell vaccine for breast cancer

2021 ◽  
Author(s):  
Guiyan Jia ◽  
Xingyue Shao ◽  
Rui Zhao ◽  
Tao Zhang ◽  
Xiechen Zhou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cell ◽  
Signaling Pathway ◽  
Mechanism Of Action ◽  
Dendritic Cell Vaccine ◽  
Portulaca Oleracea ◽  
Cell Vaccine ◽  
Dc Vaccine ◽  
Immune Efficacy ◽  
Dc Maturation

POL-P3b, as a promising dietary adjuvant for the DC vaccine of breast cancer, could induce DC maturation and the mechanism of action involved in the TLR4/MyD88/NF-κB signaling pathway.

scholarly journals Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3540
Author(s):  
Hamid Maadi ◽  
Mohammad Hasan Soheilifar ◽  
Won-Shik Choi ◽  
Abdolvahab Moshtaghian ◽  
Zhixiang Wang
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Mechanism Of Action ◽  
Mechanisms Of Action ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Insight Into ◽  
Positive Breast Cancer

Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998. Although trastuzumab has opened a new avenue to treat patients with HER2-positive breast cancer and other types of cancer, some patients are not responsive or become resistant to this treatment. So far, several mechanisms have been suggested for the mode of action of trastuzumab; however, the findings regarding these mechanisms are controversial. In this review, we aimed to provide a detailed insight into the various mechanisms of action of trastuzumab.

Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel

2021 ◽  
Vol 891 ◽  
pp. 173780
Author(s):  
Alicja Urbaniak ◽  
Sergio Piña-Oviedo ◽  
Youzhong Yuan ◽  
Adam Huczyński ◽  
Timothy C. Chambers
Keyword(s):  
Breast Cancer ◽  
Anticancer Drug ◽  
Mechanism Of Action ◽  
Ex Vivo ◽  
Cancer Model ◽  
Breast Cancer Model

Mechanism of Action of Progestins in the Treatment of Hormone-dependent Breast Cancer.

1975 ◽  
Vol 61 (6) ◽  
pp. 501-508 ◽  
Author(s):  
Francesco Di Carlo ◽  
Giovanni Pacilio ◽  
Giuseppe Conti
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptors ◽  
Mechanism Of Action ◽  
Mode Of Action ◽  
Binding Capacity ◽  
Specific Receptors ◽  
High Concentrations ◽  
Good Agreement

The in vitro interference of some gestagens with the binding of 3H-17 β-oestradiol to cytosol specific receptors was investigated with a view to elucidating the mechanism of action of progestins in the treatment of human hormone-dependent breast cancer. A decrease (up to 85 %) of oestradiol binding capacity was observed with high concentrations of progesterone, clogestone and medrogestone. These findings are in good agreement with those previously obtained by the same progestins in our laboratory on rat uterine estrogen receptors in vitro or in vivo. These results provide support for the hypothesis that the mode of action of progestins in the therapy of mammary and perhaps uterine carcinomas is to some extent related to the inhibition of oestradiol binding to cytosol specific receptors.

The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells

2019 ◽  
Vol 129 ◽  
pp. 1155-1167 ◽  
Author(s):  
Zhenhui Deng ◽  
Jinwei Chai ◽  
Qingye Zeng ◽  
Bei Zhang ◽  
Tiaofei Ye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Breast Cancer Cells ◽  
Anticancer Properties

scholarly journals Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models

2019 ◽  
Vol 30 ◽  
pp. v781-v782 ◽  
Author(s):  
A. Fiascarelli ◽  
G. Merlino ◽  
S. Capano ◽  
A. Paoli ◽  
A. Bressan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mechanism Of Action ◽  
Pi3k Inhibitor ◽  
Preclinical Models
Sign in / Sign up

Export Citation Format

Share Document